Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354649 | 1.00 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL29378263 | 1.00 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL16173690 | 0.96 | BTK (0.93) | BTKYES1FGRTECBMX | |
| SCHEMBL1726979 | 0.94 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL22945745 | 0.94 | BTK (0.92) | BTKYES1FGRTECBMX | |
| SCHEMBL22946024 | 0.94 | BTK (0.89) | BTKYES1FGRTECBMX | |
| SCHEMBL3041622 | 0.94 | BTK (0.88) | BTKYES1FGRTECBMX | |
| SCHEMBL3058691 | 0.93 | BTK (0.87) | BTKYES1FGRTECBMX | |
| SCHEMBL1727048 | 0.93 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL22946141 | 0.92 | BTK (0.87) | BTKYES1FGRTECBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-04 | — | — | US | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| CN-107872977-B | Combination of an IRAK4 inhibitor and a BTK inhibitor | 拜耳制药股份公司 | 2021-07-09 | — | — | CN | claimed |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | US | claimed |
| EP-3288558-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-07 | — | — | EP | claimed |
| EP-3195865-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | claimed |
| WO-2016174183-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | WO | claimed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | claimed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2403846-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100070-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | BTK 4274/4885YES1 3317/4885FGR 1811/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | BTK 3557/4885YES1 1688/4885FGR 1309/4885 |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CCNO, CDK2, CCNI | BTK 892/4885YES1 838/4885FGR 543/4885 |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK1, IRAK2 | BTK 5/4885YES1 494/4885FGR 4036/4885 |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK2, IRAK1 | BTK 6/4885YES1 580/4885FGR 3907/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | BTK 1148/4885YES1 710/4885FGR 1300/4885 |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885YES1 19/4885FGR 298/4885 |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | CTNND1, FLT3, MEF2D | BTK 167/4885YES1 482/4885FGR 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.